On May 30, 2023 XENOTHERA reported its participation in the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) congress, where the world’s cancer experts gather each year to share the latest clinical trial data and innovations in cancer research and education (Press release, Xenothera, MAY 30, 2023, View Source [SID1234632223]). On this occasion, XENOTHERA (Nantes, France) publishes two abstracts demonstrating the value of its technology against cancers.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
For nearly ten years, XENOTHERA has been developing innovative drugs based on its glycohumanized polyclonal antibody (GH-pAb) technology. XENOTHERA’s antibodies address major therapeutic needs in several therapeutic areas, including oncology, immunosuppression, viral and bacterial infections. XENOTHERA’s GMP platform allows for accelerated development thanks to its internal biomanufacturing facility, its clinical experience (400 patients exposed to GH-pAb), and its clinical and regulatory mastery. In less than 8 years, three of XENOTHERA’s GH-pAbs have been introduced in humans, in transplantation, Covid and infectious diseases. During clinical trials already conducted (phase I, phase II, phase III), GH-pAbs have demonstrated their safety and therapeutic potential.
At the ASCO (Free ASCO Whitepaper) congress, XENOTHERA details the properties of its fourth GH-pAb, XON7, active against solid tumors and in hematology, by publishing two abstracts. The first abstract (#421432) presents the anti-cancer activity of XON7 on more than 10 solid tumors including non-small cell lung (NSCL), pancreas, liver, colon, prostate, and several lymphomas, in vitro and in vivo. The second abstract (#421642) presents the synergy between XON7 and immune checkpoint inhibitors (ICIs) in vivo in non-small cell lung cancer.
XON7’s recognition of multiple solid tumors and its ability to act synergistically with ICIs confirms its status as a promising candidate for a new line of treatments for several cancers that affect millions of patients.
Based on fundamentally innovative and different mechanisms of action, XON7 is presented as "first in class", and limits the risk of tumor escape unfortunately observed with many treatments. The first clinical trial of XON7 is scheduled to start before the end of 2023.
XENOTHERA’s presence at ASCO (Free ASCO Whitepaper) 2023, an event known for highlighting new discoveries in optimizing patient care, improving access and developing new treatments, allows the company to raise awareness of its technology within the international medical community.